Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors

Nat Commun. 2024 Apr 5;15(1):2862. doi: 10.1038/s41467-024-46593-1.

Abstract

The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug target in BRCA1/2 mutant cancers. We discover an allosteric Polθ inhibitor (Polθi) class with 4-6 nM IC50 that selectively kills HR-deficient cells and acts synergistically with PARP inhibitors (PARPi) in multiple genetic backgrounds. X-ray crystallography and biochemistry reveal that Polθi selectively inhibits Polθ polymerase (Polθ-pol) in the closed conformation on B-form DNA/DNA via an induced fit mechanism. In contrast, Polθi fails to inhibit Polθ-pol catalytic activity on A-form DNA/RNA in which the enzyme binds in the open configuration. Remarkably, Polθi binding to the Polθ-pol:DNA/DNA closed complex traps the polymerase on DNA for more than forty minutes which elucidates the inhibitory mechanism of action. These data reveal a unique small-molecule DNA polymerase:DNA trapping mechanism that induces synthetic lethality in HR-deficient cells and potentiates the activity of PARPi.

MeSH terms

  • BRCA1 Protein* / genetics
  • BRCA2 Protein / genetics
  • DNA / metabolism
  • DNA Repair
  • DNA-Directed DNA Polymerase / metabolism
  • Homologous Recombination
  • Humans
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology

Substances

  • BRCA1 Protein
  • BRCA2 Protein
  • DNA
  • DNA-Directed DNA Polymerase
  • Poly(ADP-ribose) Polymerase Inhibitors
  • BRCA1 protein, human
  • BRCA2 protein, human